TY - JOUR
T1 - Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland
T2 - data from the COVID-19 Global Rheumatology Alliance registry
AU - Conway, Richard
AU - Nikiphorou, Elena
AU - Demetriou, Christiana A.
AU - Low, Candice
AU - Leamy, Kelly
AU - Ryan, John G.
AU - Kavanagh, Ronan
AU - Fraser, Alexander D.
AU - Carey, John J.
AU - O'connell, Paul
AU - Flood, Rachael M.
AU - Mullan, Ronan H.
AU - Kane, David J.
AU - Ambrose, Nicola
AU - Stafford, Frances
AU - Robinson, Philip C.
AU - Liew, Jean W.
AU - Grainger, Rebecca
AU - Mccarthy, Geraldine M.
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Objectives: Although evidence is accumulating globally, data on outcomes in rheumatic disease and COVID-19 in Ireland are limited. We used data from the COVID-19 Global Rheumatology Alliance (C19-GRA) to describe time-varying COVID-19 outcomes for people with rheumatic disease in Ireland. Methods: Data entered into the C19-GRA provider registry from Ireland between 24 March 2020 and 9 July 2021 were analysed. Differences in the likelihood of hospitalization and mortality according to demographic and clinical variables were investigated using Chi-squared test or Fisher's exact test, as appropriate. Trends in odds of hospitalization and mortality over time were investigated using logistic regression with the time period as a categorical variable. Results: Of 212 cases included, 59.4% were female and median age was 58.0 years (range 13-96). Of the 212 cases, 92 (43%) were hospitalized and 22 (10.4%) died. Increasing age, a diagnosis of gout, ever smoking, glucocorticoid use, having comorbidities and specific comorbidities of cancer, cardiovascular and pulmonary disease were more common in those hospitalized. A diagnosis of inflammatory arthritis, csDMARD and/or b/tsDMARD use were less frequent in those hospitalized. Increasing age, a diagnosis of gout, ever smoking, having comorbidities and specific comorbidities of obesity, cardiovascular and pulmonary disease were more common in those who died. Odds of hospitalization or mortality did not change over time. Conclusion: No temporal trend was observed in either COVID-19-related hospitalization or mortality outcomes for people with rheumatic disease in Ireland.
AB - Objectives: Although evidence is accumulating globally, data on outcomes in rheumatic disease and COVID-19 in Ireland are limited. We used data from the COVID-19 Global Rheumatology Alliance (C19-GRA) to describe time-varying COVID-19 outcomes for people with rheumatic disease in Ireland. Methods: Data entered into the C19-GRA provider registry from Ireland between 24 March 2020 and 9 July 2021 were analysed. Differences in the likelihood of hospitalization and mortality according to demographic and clinical variables were investigated using Chi-squared test or Fisher's exact test, as appropriate. Trends in odds of hospitalization and mortality over time were investigated using logistic regression with the time period as a categorical variable. Results: Of 212 cases included, 59.4% were female and median age was 58.0 years (range 13-96). Of the 212 cases, 92 (43%) were hospitalized and 22 (10.4%) died. Increasing age, a diagnosis of gout, ever smoking, glucocorticoid use, having comorbidities and specific comorbidities of cancer, cardiovascular and pulmonary disease were more common in those hospitalized. A diagnosis of inflammatory arthritis, csDMARD and/or b/tsDMARD use were less frequent in those hospitalized. Increasing age, a diagnosis of gout, ever smoking, having comorbidities and specific comorbidities of obesity, cardiovascular and pulmonary disease were more common in those who died. Odds of hospitalization or mortality did not change over time. Conclusion: No temporal trend was observed in either COVID-19-related hospitalization or mortality outcomes for people with rheumatic disease in Ireland.
KW - biologics
KW - COVID-19
KW - hospitalization
KW - rheumatic disease
UR - https://www.scopus.com/pages/publications/85133215023
U2 - 10.1093/rheumatology/keac142
DO - 10.1093/rheumatology/keac142
M3 - Article
C2 - 35258593
AN - SCOPUS:85133215023
SN - 1462-0324
VL - 61
SP - SI151-SI156
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - SI2
ER -